Adenylyl cyclases as innovative therapeutic goals.

Abstract:

:Pharmacological modulation of intracellular cyclic AMP (cAMP) signalling could provide new therapeutic and experimental tools. Although drugs interfering with this pathway have traditionally targeted membrane receptors, the effector enzyme adenylyl cyclase (AC), which functions as a signalling catalyst, also presents an interesting target. Thus, development of isoform-selective stimulator and/or inhibitor compounds for AC could lead to organ-specific pharmacotherapeutics for treating heart failure, cancer and neurodegenerative diseases. In this review, the potential of AC as the object of drug therapy is discussed.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Pavan B,Biondi C,Dalpiaz A

doi

10.1016/j.drudis.2009.07.007

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

982-91

issue

19-20

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(09)00229-3

journal_volume

14

pub_type

杂志文章,评审
  • Chronic autoimmune-mediated inflammation: a senescent immune response to injury.

    abstract::The increasing prevalence of chronic autoimmune-mediated inflammatory diseases (AIMIDs) in ageing western societies is a major challenge for the drug development industry. The current high medical need for more-effective treatments is at least in part caused by our limited understanding of the mechanisms that drive ch...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.11.010

    authors: 't Hart BA,Chalan P,Koopman G,Boots AM

    更新日期:2013-04-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)02006-2

    authors: Westwell AD

    更新日期:2001-11-15 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01410-5

    authors: Lloyd AW

    更新日期:1999-11-01 00:00:00

  • E-drug delivery: a futuristic approach.

    abstract::Drug delivery systems are undergoing technology changes to enhance patient comfort and compliance. Electronic drug delivery (E-drug delivery) systems are being developed to regulate drug dose delivery by easy monitoring of doses, especially in chronic and age-related diseases. E-drug delivery can monitor the correct d...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.02.005

    authors: Yadav KS,Kapse-Mistry S,Peters GJ,Mayur YC

    更新日期:2019-04-01 00:00:00

  • Post-approval fate of pharmaceutical companies.

    abstract::For a fortunate subset of pharmaceutical companies, a regulatory approval is the culmination of massive investment in time, work and money. What happens next? Some companies proceed to build a pipeline and obtain additional approvals. Others do not. In this present report, post-approval fate is evaluated and it was fo...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2014.10.013

    authors: Kinch MS

    更新日期:2015-02-01 00:00:00

  • Natural products in drug discovery.

    abstract::Natural products have been the single most productive source of leads for the development of drugs. Over a 100 new products are in clinical development, particularly as anti-cancer agents and anti-infectives. Application of molecular biological techniques is increasing the availability of novel compounds that can be c...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.07.004

    authors: Harvey AL

    更新日期:2008-10-01 00:00:00

  • Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins.

    abstract::Cervical cancer is the fourth most common cancer among women worldwide and its development is mainly associated with human papillomavirus infection, a highly sexually transmissible virus. The expression of E6 and E7 viral oncoproteins deregulates cell repairing mechanisms through impairment of tumor suppressor protein...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.07.011

    authors: Almeida AM,Queiroz JA,Sousa F,Sousa Â

    更新日期:2019-10-01 00:00:00

  • Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?

    abstract::The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.02.005

    authors: Alama A,Orengo AM,Ferrini S,Gangemi R

    更新日期:2012-05-01 00:00:00

  • Targeting PRAS40 for multiple diseases.

    abstract::Proline-rich Akt substrate 40kDa (PRAS40) bridges cell signaling between protein kinase B (Akt) and the mammalian target of rapamycin complex 1 (mTORC1). Both Akt and mTORC1 can phosphorylate PRAS40. As a negative regulator of mTORC1, PRAS40 prevents the binding of mTOR to its substrates. The phosphorylation of PRAS40...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.04.005

    authors: Chong ZZ

    更新日期:2016-08-01 00:00:00

  • Noncoding RNA and epigenetic gene regulation in renal diseases.

    abstract::Kidneys have a major role in normal physiology and metabolic homeostasis. Loss or impairment of kidney function is a common occurrence in several metabolic disorders, including hypertension and diabetes. Chronic kidney disease (CKD) affect nearly 10% of the population worldwide; ranks 18th in the list of causes of dea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.020

    authors: Kota SK,Kota SB

    更新日期:2017-07-01 00:00:00

  • Strategic groups in the biopharmaceutical industry: implications for performance.

    abstract::The biopharmaceutical industry is characterized by intense competition, high uncertainty, and strong dependence on scientific knowledge. We show that in order to succeed in this industry, firms need to be positioned along three strategic dimensions: the level of inter-firm R&D partnering, the level of diversification,...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2009.04.004

    authors: Erden Z,von Krogh G,Nytorp C,Hultberg M

    更新日期:2009-08-01 00:00:00

  • Can BDDCS illuminate targets in drug design?

    abstract::The fact that pharmacokinetic (PK) properties of drugs influence their interaction with protein targets is a principle known for decades. The same cannot be said for the opposite, namely that targets influence the PK properties of drugs. Evidence confirming this possibility is introduced here for the first time, as we...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.021

    authors: Bocci G,Benet LZ,Oprea TI

    更新日期:2019-12-01 00:00:00

  • Molecular diversity and its analysis.

    abstract::We have recently developed a novel strategy for the rational design of compounds. This 'in silico screening' approach is based on the design and screening of virtual combinatorial libraries. Screening is performed using defined rules derived from a comprehensive description of active and inactive molecules in a releva...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01334-3

    authors: Gorse D,Rees A,Kaczorek M,Lahana R

    更新日期:1999-06-01 00:00:00

  • Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy.

    abstract::The endocannabinoid system is implicated in, and regulates, several physiological processes, ranging from food intake and energy balance to pain and inflammation. 2-Arachidonoylglycerol (2-AG) is a full agonist at the cannabinoid receptors which classically mediate its effects. The activity of this bioactive lipid is ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.009

    authors: Alhouayek M,Masquelier J,Muccioli GG

    更新日期:2014-03-01 00:00:00

  • Gastrointestinal patch systems for oral drug delivery.

    abstract::Gastrointestinal patch systems with integrated multifunctions could surmount the challenges associated with conventional drug delivery. Several gastrointestinal patch systems provide bioadhesion, drug protection and unidirectional release. This combination of function could improve the overall oral bioavailability of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03489-6

    authors: Tao SL,Desai TA

    更新日期:2005-07-01 00:00:00

  • The botanical explorer's legacy: a promising bioprospecting tool.

    abstract::Records about the traditional uses of medicinal plants can be considered useful in bioprospecting (i.e., the search for new active agents or lead structures in nature). Several sources like Egyptian papyri, early modern herbals and pharmacopoeias have been studied in this respect. It is proposed to use recordings of b...

    journal_title:Drug discovery today

    pub_type: 历史文章,杂志文章

    doi:10.1016/j.drudis.2016.11.011

    authors: Helmstädter A

    更新日期:2017-05-01 00:00:00

  • Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils.

    abstract::Mice have been excellent surrogates for studying neutrophil biology and, furthermore, murine models of human disease have provided fundamental insights into the roles of human neutrophils in innate immunity. The emergence of novel humanized mice and high-diversity mouse populations offers the research community innova...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.03.018

    authors: Hosur V,Skelly DA,Francis C,Low BE,Kohar V,Burzenski LM,Amiji MM,Shultz LD,Wiles MV

    更新日期:2020-06-01 00:00:00

  • Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.

    abstract::Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to sel...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)02988-X

    authors: Marcucci F,Lefoulon F

    更新日期:2004-03-01 00:00:00

  • Expanding medicinal chemistry space.

    abstract::Clinically useful drugs target a relatively small number of proteins that lie within a clearly defined and chemically accessible space. However, many high value biological targets lie outside this chemical space, and an ability to access such 'intractable' targets not amenable to traditional small molecule interventio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.10.008

    authors: Barker A,Kettle JG,Nowak T,Pease JE

    更新日期:2013-03-01 00:00:00

  • Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor.

    abstract::The pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) are ligand-activated nuclear receptors (NRs) that are notorious for their role in drug metabolism, causing unintended drug-drug interactions and decreasing drug efficacy. They control the xenobiotic detoxification system by regulating the exp...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.01.021

    authors: Chai SC,Lin W,Li Y,Chen T

    更新日期:2019-03-01 00:00:00

  • Mammalian carboxylesterases: from drug targets to protein therapeutics.

    abstract::Our understanding of the detailed recognition and processing of clinically useful therapeutic agents has grown rapidly in recent years, and we are now able to begin to apply this knowledge to the rational treatment of disease. Mammalian carboxylesterases (CEs) are enzymes with broad substrate specificities that have k...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03383-0

    authors: Redinbo MR,Potter PM

    更新日期:2005-03-01 00:00:00

  • Commercially bioavailable proprietary technologies and their marketed products.

    abstract::In this review, we discuss the methodologies and platform technologies for enhancing the oral bioavailability of poorly soluble drugs. We also highlight the mechanisms of formulation technologies for improving desired physicochemical attributes of active substances. We focus on various commercial technologies, along w...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.05.007

    authors: Alam MA,Al-Jenoobi FI,Al-Mohizea AM

    更新日期:2013-10-01 00:00:00

  • Rational drug discovery: what can we learn from regulatory networks?

    abstract::To enable the list of genes and proteins contained within genomic databases to be useful for drug discovery, we need to understand how the genome maps into the phenome. An essential, but not explicitly listed ingredient of the genome is the regulatory interactions between genes and proteins that form a genome-wide net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02463-7

    authors: Huang S

    更新日期:2002-10-15 00:00:00

  • Opportunities for novel therapeutic agents acting at chemokine receptors.

    abstract::Chemokines are proinflammatory mediators that primarily control leukocyte migration into selected tissues and upregulation of adhesion receptors. They also have a role in pathological conditions that require neovascularization and are implicated in the suppression of viral replication. By interaction with their respec...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01280-x

    authors: Saunders J,Tarby CM

    更新日期:1999-02-01 00:00:00

  • Fetal hypoxia and programming of matrix metalloproteinases.

    abstract::Fetal hypoxia adversely affects the brain and heart development, yet the mechanisms responsible remain elusive. Recent studies indicate an important role of the extracellular matrix in fetal development and tissue remodeling. The matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of me...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.09.011

    authors: Tong W,Zhang L

    更新日期:2012-02-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01566-x

    authors: Edwards P

    更新日期:2000-10-01 00:00:00

  • Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems.

    abstract::Quercetin is reported to have numerous pharmacological actions, including antidiabetic, anti-inflammatory and anticancer activities. The main mechanism responsible for its pharmacological activities is its ability to quench reactive oxygen species (ROS) and, hence, decrease the oxidative stress responsible for the dev...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.001

    authors: Khursheed R,Singh SK,Wadhwa S,Gulati M,Awasthi A

    更新日期:2020-01-01 00:00:00

  • Pharmaceutical approaches to the treatment of obesity.

    abstract::The recent increase in pharmaceutical companies' efforts toward the treatment of obesity reflects recognition of the related health risks, the growth of knowledge about mechanisms that control energy balance, and the potential market for new compounds. The current patent literature gives a picture of the targets that ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03244-1

    authors: Jandacek RJ,Woods SC

    更新日期:2004-10-15 00:00:00

  • Chemical proteomics and its application to drug discovery.

    abstract::The completion of the human genome sequencing project has provided a flood of new information that is likely to change the way scientists approach the study of complex biological systems. A major challenge lies in translating this information into new and better ways to treat human disease. The multidisciplinary scien...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:

    authors: Jeffery DA,Bogyo M

    更新日期:2004-01-15 00:00:00

  • The druggable genome: an update.

    abstract::Annotating the druggable genome estimates the potential maximum size of the playing field for current small-molecule drug design but It does not consider biologicals or future breakthroughs in medicinal chemistry or biology. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03666-4

    authors: Russ AP,Lampel S

    更新日期:2005-12-01 00:00:00